Developments in Research on the Relationship Between Porphyromonas gingivalis and Non-Oral Diseases

ZHANG Ke-ke, SUN Yan, PAN Yi-huai

Abstract

Porphyromonas gingivalis (P. gingivalis) is a common periodontal pathogen. Recently, there has been increasing evidence suggesting that P. gingivalis is not only a common pathogen in the oral cavity, but is also closely associated with non-oral diseases, including inflammatory bowel disease, cancer, cardiovascular diseases, Alzheimer's disease, rheumatoid arthritis, diabetes mellitus, premature birth and non-alcoholic hepatitis, etc. Herein, we reviewed the developments in recent years in research on the relationship between P. gingivalis, a periodontal pathogen, and non-oral diseases, which will help determine whether P. gingivalis could be used as an auxiliary diagnostic biomarker or a potential therapeutic target for these non-oral diseases, thus contributing to the development of treatment strategies for the relevant diseases.

 

Keywords: Porphyromonas gingivalis, Non-oral diseases, Correlation

 

Full Text:

PDF


References


PAPAGEORGIOU S N， HAGNER M， NOGUEIRA A， et al. Inflammatory bowel disease and oral health: systematic review and a meta‐analysis. J Clin Periodontol，2017，44(4): 382–393. doi: 10.1111/jcpe. 12698.

JIA L， WU R， HAN N， et al. Porphyromonas gingivalis and Lactobacillus rhamnosus GG regulate the Th17/Treg balance in colitis via TLR4 and TLR2. Clin Transl Immunology，2020，9(11): e1213. doi: 10. 1002/cti2.1213.

ZHAO X， LIU J， ZHANG C， et al. Porphyromonas gingivalis exacerbates ulcerative colitis via Porphyromonas gingivalis peptidylarginine deiminase. Int J Oral Sci，2021，13(1): 31. doi: 10.1038/s41368-021-00136-2.

TSUZUNO T， TAKAHASHI N， YAMADA-HARA M， et al. Ingestion of Porphyromonas gingivalis exacerbates colitis via intestinal epithelial barrier disruption in mice. J Periodontal Res，2021，56(2): 275–288. doi: 10.1111/jre.12816.

LEE Y C， LIU C Y， LEE C L， et al. The periodontopathic pathogen, Porphyromonas gingivalis, involves a gut inflammatory response and exacerbates inflammatory bowel disease. Pathogens，2022，11(1): 84. doi: 10.3390/pathogens11010084.

SOHN J， LI L， ZHANG L， et al. Porphyromonas gingivalis indirectly elicits intestinal inflammation by altering the gut microbiota and disrupting epithelial barrier function through IL9-producing CD4+ T cells. Mol Oral Microbiol，2022，37(2): 42–52. doi: 10.1111/omi.12359.

SINHA R， AHN J， SAMPSON J N， et al. Fecal microbiota, fecal metabolome, and colorectal cancer interrelations. PLoS One，2016，1(3): e0152126. doi: 10.1371/journal.pone.0152126.

PURCELL R V， VISNOVSKA M， BIGGS P J， et al. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Sci Rep，2017，7(1): 11590. doi: 10.1038/s41598-017-11237-6.

MU W， JIA Y， CHEN X， et al. Intracellular Porphyromonas gingivalis promotes the proliferation of colorectal cancer cells via the MAPK/ERK signaling pathway. Front Cell Infect Microbiol，2020，10: 584798. doi: 10. 3389/fcimb.2020.584798.

ADEL-KHATTAB D， GROEGER S， DOMANN E， et al. Porphyromonas gingivalis induced up-regulation of PD-L1 in colon carcinoma cells. Mol Oral Microbiol，2021，36(3): 172–181. doi: 10.1111/omi.12332.

WANG X， JIA Y， WEN L， et al. Porphyromonas gingivalis promotes colorectal carcinoma by activating the hematopoietic NLRP3 inflammasome. Cancer Res，2021，81(10): 2745–2759. doi: 10.1158/0008-5472.CAN-20-3827.

MICHAUD D S， IZARD J， WILHELM-BENARTZI C S， et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large european prospective cohort study. Gut，2013，62(12): 1764–1770. doi: 10. 1136/gutjnl-2012-303006.

FAN X， ALEKSEYENKO A V， WU J， et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut，2018，67(1): 120–127. doi: 10.1136/gutjnl-2016-312580.

GNANASEKARAN J， BINDER GALLIMIDI A， SABA E， et al. Intracellular Porphyromonas gingivalis promotes the tumorigenic behavior of pancreatic carcinoma cells. Cancers (Basel)，2020，12(8): 2331. doi: 10.3390/cancers12082331.

HIRAKI D， UEHARA O， KURAMITSU Y， et al. P.gingivalis lipopolysaccharide stimulates the upregulated expression of the pancreatic cancer-related genes regenerating islet-derived 3 a/g in mouse pancreas. Int J Mol Sci，2020，21(19): 7351. doi: 10.3390/ijms21197351.

CHEN S M， HSU L J， LEE H L， et al. Lactobacillus attenuate the progression of pancreatic cancer promoted by Porphyromonas gingivalis in K-rasG12D transgenic mice. Cancers (Basel)，2020，12(12): 3522. doi: 10.3390/cancers12123522.

TAN Q， MA X， YANG B， et al. Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils. Gut Microbes，2022，14(1): 2073785. doi: 10.1080/19490976.2022.2073785.

GAO S， LI S， MA Z， et al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infect Agent Cancer， 2016，11: 3. doi: 10.1186/s13027-016-0049-x.

GAO S G， YANG J Q， MA Z K， et al. Preoperative serum immunoglobulin g and a antibodies to Porphyromonas gingivalis are potential serum biomarkers for the diagnosis and prognosis of esophageal squamous cell carcinoma. BMC Cancer，2018，18(1): 17. doi: 10.1186/s12885-017-3905-1.

MENG F， LI R， MA L， et al. Porphyromonas gingivalis promotes the motility of esophageal squamous cell carcinoma by activating NF-κB signaling pathway. Microbes Infect，2019，21(7): 296–304. doi: 10.1016/j. micinf.2019.01.005.

LIANG G， WANG H， SHI H， et al. Porphyromonas gingivalis promotes the proliferation and migration of esophageal squamous cell carcinoma through the miR-194/GRHL3/PTEN/AKT axis. ACS Infect Dis，2020， 6(5): 871–881. doi: 10.1021/acsinfecdis.0c00007.

CHEN M F， LU M S， HSIEH C C， et al. Porphyromonas gingivalis promotes tumor progression in esophageal squamous cell carcinoma. Cell Oncol (Dordr)，2021，44(2): 373–384. doi: 10.1007/s13402-020-00573-x.

GAO S， LIU Y， DUAN X， et al. Porphyromonas gingivalis infection exacerbates oesophageal cancer and promotes resistance to neoadjuvant chemotherapy. Br J Cancer，2021，125(3): 433–444. doi: 10.1038/s41416-021-01419-5.

GUO Y， LIU Y， YANG H， et al. Associations of Porphyromonas gingivalis infection and low beclin1 expression with clinicopathological parameters and survival of esophageal squamous cell carcinoma patients. Pathol Oncol Res，2021，27: 1609976. doi: 10.3389/pore.2021.1609976.

CHUNG M， YORK B R， MICHAUD D S. Oral health and cancer. Curr Oral Health Rep，2019，6(2): 130–137. doi: 10.1007/s40496-019-0213-7.

LIU Y， YUAN X， CHEN K， et al. Clinical significance and prognostic value of Porphyromonas gingivalis infection in lung cancer. Transl Oncol， 2021，14(1): 100972. doi: 10.1016/j.tranon.2020.100972.

SCHENKEIN H A， PAPAPANOU P N， GENCO R， et al. Mechanisms underlying the association between periodontitis and atherosclerotic disease. Periodontol 2000，2020，83(1): 90–106. doi: 10.1111/prd.12304.

XIE M， TANG Q， YU S， et al. Porphyromonas gingivalis disrupts vascular endothelial homeostasis in a TLR-NF-κB axis dependent manner. Int J Oral Sci，2020，12(1): 28. doi: 10.1038/s41368-020-00096-z.

MEI F， XIE M， HUANG X， et al. Porphyromonas gingivalis and its systemic impact: current status. Pathogens，2020，9(11): 944. doi: 10.3390/pathogens9110944.

ZHANG J， XIE M， HUANG X， et al. The effects of Porphyromonas gingivalis on atherosclerosis-related cells. Front Immunol，2021，12: 766560. doi: 10.3389/fimmu.2021.766560.


Refbacks

  • There are currently no refbacks.